Thermedical is developing preclinical prototypes for a Saline-Enhanced Radio Frequency (SERF) ablation system for treating malignant solid tissue, such as liver cancer, and for difficult-to-treat cardiac arrhythmias, such as ventricular tachycardia (VT).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/20/12 | $1,500,000 | Series A |
Samuel H. Maslak | undisclosed |
| 05/15/13 | $5,500,000 | Series A-2 |
Karl H. Johannsmeier Samuel H. Maslak | undisclosed |
